Home / Weight & metabolism / Survodutide
SuHuman trials

Survodutide protocol

Survodutide is a weekly injection from Boehringer Ingelheim that works on the glucagon and GLP-1 receptors. It is still being tested and is not approved. Phase 3 obesity results came out in 2026.

Not approved anywhere (investigational)Phase 3 SYNCHRONIZE-1 finished; liver (MASH) phase 3 trials running
ProtocolMixingResultsSide effectsHow it worksSources

The protocol at a glance

In the phase 3 trial, people injected survodutide weekly, with the amount raised slowly to a top of 3.6 mg or 6.0 mg, for 76 weeks.

StudyWeekly amount
Phase 3 obesity, 76 weeksRaised up to 3.6 mg or 6.0 mg (step-up plan not in the sources I checked)
Phase 2 obesity, 46 weeks0.6, 2.4, 3.6 or 4.8 mg (20 weeks raising, 26 weeks steady)
Phase 2 liver disease (MASH), 48 weeks2.4, 4.8 or 6.0 mg (24 weeks raising, 24 weeks steady)

From the SYNCHRONIZE-1 NEJM 2026 abstract and registry (NCT06066515), the Lancet Diabetes & Endocrinology 2024 phase 2 paper (NCT04667377), and the NEJM 2024 MASH paper (NCT04771273). These are trial schedules. No label exists.

Community reports

Community notes tend to copy trial numbers and start low. This is community talk, not a label.

What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.

Mixing calculator

Enter the vial size, the water you add and the amount you want to draw; it gives the mark on a 100-unit (1 mL) insulin syringe.

Draw to – units

What the trials found

SYNCHRONIZE-1: 725 adults with obesity, no diabetes, 76 weeks. Average body weight change (treatment-regimen analysis, which includes people who stopped early):

-13.0%6.0 mg weekly
-12.2%3.6 mg weekly
-5.4%Placebo
72%lost 5% or more (both doses), vs 46% on placebo

NEJM 2026 (SYNCHRONIZE-1, NCT06066515). The company's earlier headline of up to 16.6% used a different analysis (efficacy estimand, assumes the drug was taken as planned).

Side effects

  • Stomach and gut effects were the most common: 81% on 3.6 mg and 90% on 6.0 mg, versus 48% on placebo. They were usually mild to moderate. No deaths were reported.
  • In the liver trial, nausea was 66% vs 23% on placebo, diarrhea 49% vs 23%, and vomiting 41% vs 4%.

How it works

GLP-1 receptor

Switches on the GLP-1 receptor, which lowers appetite.

Glucagon receptor

Also switches on the glucagon receptor. The liver trial studied it for fatty liver disease (MASH).

Sources

  • Survodutide once weekly for the treatment of adults with obesity. N Engl J Med 2026 (SYNCHRONIZE-1), NCT06066515
  • Survodutide for obesity, phase 2. Lancet Diabetes Endocrinol 2024, NCT04667377
  • Sanyal AJ et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 2024, NCT04771273
  • ClinicalTrials.gov NCT06066515, NCT06632444 (LIVERAGE, recruiting)